Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
Ocular Therapeutix reported second quarter 2026 total net revenue of $13.5 million, essentially unchanged from a year earlier, and a net loss of $(78.8) million, or $(0.35) per share. Cash and cash equivalents were $598.6 million as of June 30, 2026, which the company believes will fund planned operating expenses, debt service and capital spending into 2028 based on current plans.
The company is prioritizing AXPAXLI (OTX-TKI) for wet age-related macular degeneration. After a positive FDA Type C meeting, it plans to submit a wet AMD NDA in Q4 2026 via the Section 505(b)(2) pathway, following a pre-NDA meeting in Q3 2026. The NDA is expected to rely on Phase 3 SOL-1 Week 52 efficacy and safety data, interim SOL-R safety data, and confirmatory evidence. In SOL-1, 74.1% of AXPAXLI-treated subjects maintained vision at Week 36 and 65.9% at Week 52, both statistically superior to aflibercept. A post-hoc analysis estimates up to a 72% reduction in intravitreal injection burden over 60 weeks versus a projected on-label aflibercept regimen.
BlackRock, Inc. reports its beneficial ownership of common stock of Ocular Therapeutix, Inc. on an amended Schedule 13G. As of June 30, 2026, BlackRock beneficially owned 15,227,768 shares of common stock, representing 7.0% of the outstanding class.
BlackRock has sole voting power over 14,910,631 shares and sole dispositive power over all 15,227,768 shares, with no shared voting or dispositive power. Various underlying clients have economic interests in these shares, but no single client holds more than five percent of Ocular Therapeutix’s outstanding common stock.
OCULAR THERAPEUTIX, INC director and officer Pravin Dugel reported bona fide gifts of Common Stock. On June 16, 2026, he reported two gift transactions totaling 100,184 shares, including 50,092 shares transferred to his spouse for no consideration.
After these transactions, Dugel reports 2,547,078 shares held directly, 694,811 shares held indirectly through the Pravin Dugel 2024 Irrevocable Trust, and 50,092 shares held indirectly by his spouse.
Ocular Therapeutix director Charles M. Warden received new equity awards as part of board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, boosting his direct holdings to 100,464 shares.
He was also granted options for 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest in full on the first anniversary of the grant date, or earlier immediately before the next annual stockholder meeting, as long as he remains on the board.
Ocular Therapeutix director Adrienne L. Graves received new equity awards as part of her board compensation. She was granted 14,000 restricted stock units, each representing one share of common stock, increasing her direct common stock holdings to 64,000 shares after the award.
She was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest 100% on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving on the board.
Ocular Therapeutix Chief Financial Officer Jason Shand Robins received new equity awards as part of his compensation. He was granted 15,441 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 68,097 shares after the award. He was also granted an option to buy 14,024 shares of common stock at an exercise price of $8.74 per share, expiring in 2036. The RSUs vest over three years in three equal annual installments, and the stock option vests monthly over four years, both contingent on his continued service with the company.
Hong Seung Suh reported acquisition or exercise transactions in this Form 4 filing.
Ocular Therapeutix director Seung Suh Hong received new equity awards as part of board compensation. He was granted 14,000 restricted stock units, each representing one future share of common stock, and 44,000 stock options to buy common shares at $8.74 per share.
The awards vest in full on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, as long as he continues serving on the board. After the grant, he directly holds 60,933 common shares and 44,000 options.
Ocular Therapeutix director Richard L. Lindstrom, MD received new equity awards as board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, and 44,000 stock options with an exercise price of $8.74 per share expiring on June 9, 2036.
Both the RSUs and options vest 100% on the first anniversary of the grant date or, if earlier, immediately before the next annual meeting of stockholders, provided he continues to serve on the board. Following the RSU grant, he directly owns 260,933 common shares.
Ocular Therapeutix director Merilee Raines received new equity awards. On June 10, 2026, she was granted 14,000 restricted stock units, each representing one share of common stock, under the company’s 2021 Stock Incentive Plan.
Subject to her continued board service, these RSUs vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, whichever comes first. She also received stock options for 44,000 shares at an exercise price of $8.74 per share, expiring on June 9, 2036, with similar vesting conditions. Following the grant, she directly holds 60,933 shares of common stock, in addition to the new option award.